. 2016 Dec 20;34(2):495–512. doi: 10.1007/s12325-016-0464-9

Table 9.

Median overall survival in months: patients with late metastatic melanoma (stage IV M1b/c)

Drug	Unadjusted	Modified Korn adjustment
GM-CSF^a	15.9	NA
Dacarbazine^b	NR	14.1
gp100	NR	9.2

GM-CSF granulocyte-macrophage colony-stimulating factor, gp100 glycoprotein 100, NA not applicable, NR not reported; however, the adjusted data exist because, for gp100 and dacarbazine, the entire stage IIIB–IV data were used

^aObserved median overall survival, ^b Based on pooled analysis of four dacarbazine curves